Navigation Links
Semiconductor Manufacturing International Corporation: Announcement of 2009 Annual Results
Date:4/26/2010

Our research and development in the Micro- Electromechanical System (MEMS) areas also advanced to risk production for the first customer in 2009. Other areas of phase- change memory, HV, mix-signal-signal, and radio frequency (RF) technologies were also successfully developed for smaller size, less power, and lower cost to meet customer demands.

We employ approximately 700 research and development engineers, with experience in the semiconductor industry and with advanced degrees from leading universities around the world and in China.

Litigation

The Company settled all pending litigation with TSMC on November 9, 2009, with a Settlement Agreement (the "2009 Settlement Agreement"). The 2009 Settlement Agreement resolved all pending lawsuits between the parties and the parties have since dismissed all pending litigation between them, including the counterclaims the Company filed against TSMC in the California case, which had not yet been decided. The terms of the 2009 Settlement Agreement include the following:

    1) Entry of judgement and mutual release of all claims that were or could
       have been brought in the pending lawsuits;
    2) Termination of SMIC's obligation to make remaining payments under prior
       settlement agreement between the parties (approximately US$40 million);
    3) Payment to TSMC of an aggregate of US$200 million (with US$15 million
       paid upon execution, funded from SMIC's existing cash balances, and the
       remainder to be paid in installments over a period of four years -
       US$15 million payable by December 31, 2009, US$80 million payable by
       December 31, 2010, US$30 million payable by December 31, 2011, US$30
       million payable by December 31, 2012 and US$30 million payable by
       December
'/>"/>
SOURCE Semiconductor Manufacturing International Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology news :

1. UNH chemists create molecule with promising semiconductor properties
2. Audience Selected as Silver Winner in This Years Wall Street Journal Technology Innovation Awards and Winner of the Semiconductors Category
3. Manufacturing antibodies
4. Louisiana Techs Institute for Micromanufacturing to collaborate with colleagues in the arts
5. ExcellGene SA first company to offer contract manufacturing in 250 Liter OrbShake bioreactor
6. Caltech scientists create DNA tubes with programmable sizes for nanoscale manufacturing
7. bioMETRX Expands Engineering and Manufacturing Capabilities
8. Nanotube-producing bacteria show manufacturing promise
9. Major funding boost for International Barcode of Life project
10. HIV prevention research focus of International Microbicides Conference May 22-25
11. International research team discovers novel genes influencing kidney disease risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 22, 2015 Infinisource has launched its ... the G2 model. The G2 sets a higher standard for ... human capital management solution. With plug-and-play installation, touch screen interface ... clock provides a robust time collection solution for the small ...
(Date:12/22/2014)... , Dec. 22, 2014  NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, announces it ... Robbins for the 2015 International CES debut of the ... will be at the NXT-ID booth January 6th and ...
(Date:12/22/2014)... Holiday Season may be the brightest ever for the ... long anticipated floodgates for consumer biometrics may finally be ... tablets, and wearable mobile devices that incorporate biometrics will ... nearly 4.8 billion biometric devices by 2020.   ...
Breaking Biology News(10 mins):Infinisource's NXG series sets new time clock standard 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2
... DIEGO , Nov. 14, 2013  Shareholder rights law firm ... Vical Incorporated (NASDAQ: VICL ) has filed a ... Court for the Southern District of California.  The complaint alleges ... Securities and Exchange Act of 1934 between February, 8, 2012 ...
... baboons at the Texas Biomedical Research Institute may help ... bisphosphonates are at-risk for atypical fractures in the long ... M. Havill, Ph.D. and colleagues at the Southwest Research ... and found differences in the microstructure of their femurs ...
... resistance is an international reality whose solution includes better ... disease physician. "The big problem is the overuse ... can they lead to side effects like rashes and ... of multidrug-resistant organisms," said Dr. Josѐ A. Vazquez, Chief ...
Cached Biology News:Attention Vical Incorporated Investors: Vical Misled Investors According to a Newly Filed Class Action 2New studies may explain fractures in some who take osteoporosis drugs 2Antibiotic resistance is a international issue that better education can address 2
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently was invited to ... on probiotics in San Diego, CA. , The Scripps ... health care professionals. This year’s pre-conference seminar was held on ... Dr. Leyer spoke about the emerging topics and science in ...
(Date:1/22/2015)... , 22 de enero de 2015  El Dr. ... su llamada a nominaciones para 2015. Este prestigioso premio ... o tiene el potencial para hacer, contribuciones destacadas para ... aceptarán hasta el 15 de marzo de 2015 a ...
(Date:1/22/2015)... Jan. 22, 2015  Derma Sciences, Inc. (Nasdaq: ... on advanced wound care, announces that AMNIOEXCEL® and ... been added to the Premier, Inc. Regenerative Skin ... for the AMNIOEXCEL® and AMNIOMATRIX® product lines, which ...
(Date:12/24/2014)... Dec. 24, 2014  Vermillion, Inc. (Nasdaq:   VRML), ... announced today that the Company closed its previously ... Management, Jack W. Schuler , Birchview Fund ... $10.5 million, before offering expenses.  The proceeds will ...
Breaking Biology Technology:El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3
... announced today that it has completed patient enrollment ... company,s investigational,once-daily oral anti-cancer drug, for the second-line ... studies -- ZODIAC (ZACTIMA in,cOmbination with Docetaxel In ... Alimta in Lung cancer) -- are the second ...
... DIEGO, March 12 Volcano Corporation,(Nasdaq: VOLC ... and,functional measurement (FM) products designed to enhance the ... said today that it,will be participating in the ... Monday, March 17., The presentation by Scott ...
... March 12 Allergy Standards LTD,("ASL"), the internationally ... its participation at the 2008 American Academy of,Allergy, ... in,Philadelphia, PA March 14th-18th., "The AAAAI conference ... research work in the asthma and allergy spaces," ...
Cached Biology Technology:AstraZeneca Completes Enrollment in Two Pivotal Phase III Studies of the Investigational Drug Vandetanib (ZACTIMA(R)) in Non-Small Cell Lung Cancer (NSCLC) 2AstraZeneca Completes Enrollment in Two Pivotal Phase III Studies of the Investigational Drug Vandetanib (ZACTIMA(R)) in Non-Small Cell Lung Cancer (NSCLC) 3Volcano Corporation Presentation at Cowen Healthcare Conference to be Webcast 2